Leisheng Wang

Dr. Leisheng Wang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2024 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Open access
XWXichen Wang
Xichen Wang
QWQingwen Wang
Qingwen Wang
Chunfu ZhengChunfu Zheng
Chunfu Zheng
LWLeisheng Wang
Leisheng Wang
The mitochondrial antiviral signaling protein (MAVS) is a pivotal adaptor in the antiviral innate immune signaling pathway and plays a crucial role in the activation of antiviral defences. This comprehensive review delves into the multifaceted functions of MAVS, spanning from its integral role in the RIG-I-like receptor (RLR) pathway to its emerging roles in tumor biology and autoimmune diseases. We discuss the structural and functional aspects of MAVS, its activation mechanisms, and the intricate regulatory networks that govern its activity. The potential of MAVS as a therapeutic target has been explored, highlighting its promise in personalized cancer therapy and developing combination treatment strategies. Additionally, we compare it with the STING signaling pathway and discuss the synergistic potential of targeting both pathways in immunotherapy. Our review underscores the importance of MAVS in maintaining immune homeostasis and its implications for a broad spectrum of diseases, offering new avenues for therapeutic intervention.

2 July 2024 in European Journal of Oncology Nursing
Verified
Journal Article
Open access
YTYue Tao
Yue Tao
YZYan Zhang
Yan Zhang
JCJie Chen
Jie Chen
LWLeisheng Wang
Leisheng Wang
NZNa Zhu
Na Zhu
HHHao Hu
Hao Hu
To evaluate the effectiveness of the PRECEDE-PROCEED model (PPM) in helping patients with liver cancer be aware of their knowledge, skills, and abilities in self-oral health behaviors and improve their oral health status. This is a quasi-experimental study of 90 patients with liver cancer assigned to an oral health education or a control group. The intervention group was educated with the PRECEDE-PROCEED model. A brief oral scale and the knowledge, attitude, and practice oral health questionnaire were employed to measure the oral health status and cognitive behavioral ability to seek oral health in patients. Among 102 eligible patients, 90 (88.23%) agreed to participate in the present study and were divided to intervention (n = 45) or control (n = 45) groups. After the intervention and one month after discharge, the oral health scores of patients in the Intervention group were lower than those of the control group (P < 0.05). In addition, after the intervention and one month after discharge, the patients in the test group had higher scores on knowledge, beliefs, and behaviors of oral health than the control group (P < 0.05). One month after discharge, the mean knowledge and skills scores were significantly higher in the intervention group than in the control group. Our findings suggest that oral health education may be a useful health intervention for patients with liver cancer. It may also improve the knowledge and beliefs of liver cancer patients seeking oral health. Larger long-term investigations are necessary to provide more support for these preliminary conclusions.

27 March 2026 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SSShu-Wen Shi
Shu-Wen Shi
YFYi-Fei Fu
Yi-Fei Fu
XWXian Wu
Xian Wu
LWLeisheng Wang
Leisheng Wang
ZZZhen-Yu Zhang
Zhen-Yu Zhang
JYJun-Xing Ye
Jun-Xing Ye

15 April 2025 in World Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
XXXia Xiao
Xia Xiao
QWQing-Wen Wang
Qing-Wen Wang
ZZZheng-Yang Zhou
Zheng-Yang Zhou
LWLeisheng Wang
Leisheng Wang
PHPei Huang
Pei Huang
BACKGROUND Although targeted therapy provides survival benefits for patients with metastatic colorectal cancer, some patients develop resistance to these treatments. Human epidermal growth factor receptor 2 (HER2) is overexpressed in a subset of patients with colorectal cancer and has been established as a therapeutic target. CASE SUMMARY This case report describes a Chinese patient with HER2-amplified advanced rectal cancer who showed no response to chemotherapy and targeted therapies against epidermal growth factor receptor and vascular endothelial growth factor but achieved a remarkable response following treatment with immune checkpoint inhibitors (ICIs) in combination with pyrotinib. The combination of oxaliplatin and ICIs with pyrotinib demonstrates synergistic effects after late-stage disease progression. CONCLUSION ICIs and pyrotinib may be effective in treating HER2-amplified advanced rectal cancer. Chemotherapy following disease progression could enhance efficacy synergistically.